Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(18):1259; doi:10.1093/jnci/djj399
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Breast Cancer Survival and Aromatase Inhibitors

It is unclear whether treating breast cancer patients with aromatase inhibitors and inactivators offers a survival benefit compared with more traditional hormone therapies such as tamoxifen. Mauri et al. (p. 1285) performed a meta-analysis of randomized controlled trials that compared several generations of aromatase inhibitors and inactivators with standard hormone therapy in advanced breast cancer patients. They found statistically significant survival benefits with third-generation aromatase inhibitors and inactivators but not with earlier agents. The authors conclude that aromatase inhibition, particularly with third-generation drugs, may be associated with improved survival . . . [Full Text of this Article]

Idiotype Vaccination in Follicular Lymphoma

Radiation Therapy in Older Women with DCIS

Kidney Cancer Incidence, Treatment, and Mortality

Estrogen Metabolism and Endometrial Cancer

Autoimmune Conditions and Hodgkin Lymphoma

Determining Disease-Free Survival Using Medicare Data

Soy and Breast Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?